Search

Your search keyword '"Wu, Chin-Lee"' showing total 1,118 results
Start Over Author "Wu, Chin-Lee"
1,118 results on '"Wu, Chin-Lee"'

301. PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53

Author

Liu, Qi, primary, Gheorghiu, Liliana, additional, Drumm, Michael, additional, Clayman, Rebecca, additional, Eidelman, Alec, additional, Wszolek, Matthew F., additional, Olumi, Aria, additional, Feldman, Adam, additional, Wang, Meng, additional, Marcar, Lynnette, additional, Citrin, Deborah E., additional, Wu, Chin-Lee, additional, Benes, Cyril H., additional, Efstathiou, Jason A., additional, and Willers, Henning, additional

Published
2018
Full Text
View/download PDF

302. Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression

Author

Ren, Shancheng, primary, Wei, Gong-Hong, additional, Liu, Dongbing, additional, Wang, Liguo, additional, Hou, Yong, additional, Zhu, Shida, additional, Peng, Lihua, additional, Zhang, Qin, additional, Cheng, Yanbing, additional, Su, Hong, additional, Zhou, Xiuqing, additional, Zhang, Jibin, additional, Li, Fuqiang, additional, Zheng, Hancheng, additional, Zhao, Zhikun, additional, Yin, Changjun, additional, He, Zengquan, additional, Gao, Xin, additional, Zhau, Haiyen E., additional, Chu, Chia-Yi, additional, Wu, Jason Boyang, additional, Collins, Colin, additional, Volik, Stanislav V., additional, Bell, Robert, additional, Huang, Jiaoti, additional, Wu, Kui, additional, Xu, Danfeng, additional, Ye, Dingwei, additional, Yu, Yongwei, additional, Zhu, Lianhui, additional, Qiao, Meng, additional, Lee, Hang-Mao, additional, Yang, Yuehong, additional, Zhu, Yasheng, additional, Shi, Xiaolei, additional, Chen, Rui, additional, Wang, Yang, additional, Xu, Weidong, additional, Cheng, Yanqiong, additional, Xu, Chuanliang, additional, Gao, Xu, additional, Zhou, Tie, additional, Yang, Bo, additional, Hou, Jianguo, additional, Liu, Li, additional, Zhang, Zhensheng, additional, Zhu, Yao, additional, Qin, Chao, additional, Shao, Pengfei, additional, Pang, Jun, additional, Chung, Leland W.K., additional, Xu, Jianfeng, additional, Wu, Chin-Lee, additional, Zhong, Weide, additional, Xu, Xun, additional, Li, Yingrui, additional, Zhang, Xiuqing, additional, Wang, Jian, additional, Yang, Huanming, additional, Wang, Jun, additional, Huang, Haojie, additional, and Sun, Yinghao, additional

Published
2018
Full Text
View/download PDF

303. An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer

Author

Miyamoto, David T., primary, Lee, Richard J., additional, Kalinich, Mark, additional, LiCausi, Joseph A., additional, Zheng, Yu, additional, Chen, Tianqi, additional, Milner, John D., additional, Emmons, Erin, additional, Ho, Uyen, additional, Broderick, Katherine, additional, Silva, Erin, additional, Javaid, Sarah, additional, Kwan, Tanya Todorova, additional, Hong, Xin, additional, Dahl, Douglas M., additional, McGovern, Francis J., additional, Efstathiou, Jason A., additional, Smith, Matthew R., additional, Sequist, Lecia V., additional, Kapur, Ravi, additional, Wu, Chin-Lee, additional, Stott, Shannon L., additional, Ting, David T., additional, Giobbie-Hurder, Anita, additional, Toner, Mehmet, additional, Maheswaran, Shyamala, additional, and Haber, Daniel A., additional

Published
2018
Full Text
View/download PDF

304. Genomic profiling of muscle invasive bladder cancer to predict response to bladder-sparing trimodality therapy.

Author

Miyamoto, David Tomoaki, primary, Gibb, Ewan, additional, Mouw, Kent William, additional, Liu, Yang, additional, Wu, Chin-Lee, additional, Drumm, Michael, additional, Lehrer, Jonathan, additional, Ashab, Hussam Al-Deen, additional, Erho, Nicholas, additional, Du Plessis, Marguerite, additional, Ong, Kaye, additional, Shipley, William U., additional, Davicioni, Elai, additional, and Efstathiou, Jason A., additional

Published
2018
Full Text
View/download PDF

305. Selective bladder preservation with twice-daily radiation plus 5-flourouracil/cisplatin (FCT) or daily radiation plus gemcitabine (GD) for patients with muscle invasive bladder cancer: Primary results of NRG/RTOG 0712—A randomized phase 2 multicenter trial.

Author

Coen, John J, primary, Zhang, Peixin, additional, Saylor, Philip James, additional, Lee, Cheryl T., additional, Wu, Chin-Lee, additional, Parker, William, additional, Lautenschlaeger, Tim, additional, Zietman, Anthony L., additional, Efstathiou, Jason A., additional, Jani, Ashesh B., additional, Kucuk, Omer, additional, Souhami, Luis, additional, Rodgers, Joseph P, additional, Sandler, Howard M., additional, and Shipley, William U., additional

Published
2018
Full Text
View/download PDF

309. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy

Author

Krasnow, Ross E., primary, Drumm, Michael, additional, Roberts, Hannah J., additional, Niemierko, Andrzej, additional, Wu, Chin-Lee, additional, Wu, Shulin, additional, Zhang, Jing, additional, Heney, Niall M., additional, Wszolek, Matthew F., additional, Blute, Michael L., additional, Feldman, Adam S., additional, Lee, Richard J., additional, Zietman, Anthony L., additional, Shipley, William U., additional, and Efstathiou, Jason A., additional

Published
2017
Full Text
View/download PDF

312. MP17-07 ANDROGENIC TO ESTROGENIC SWITCH IN PROSTATE GLAND AS A RESULT OF EPIGENETIC SILENCING OF STEROID 5-? REDUCTASE 2

Author

Wang, Zongwei, primary, Hu, Libing, additional, Ge, Rongbin, additional, Salari, Keyan, additional, Bechis, Seth, additional, Wu, Shulin, additional, Rassoulian, Cyrus, additional, Pham, Jonathan, additional, Tabetabaei, Shahin, additional, Wu, Chin-Lee, additional, Strand, Douglas, additional, and Olumi, Aria, additional

Published
2017
Full Text
View/download PDF

313. Evaluation of Tissue Metabolites with High Resolution Magic Angle Spinning MR Spectroscopy Human Prostate Samples After Three-Year Storage at -80ºC

Author

Jordan, Kate W., He, Wenlei, Halpern, Elkan F., Wu, Chin-Lee, and Cheng, Leo L.

Subjects
Pharmacology, lcsh:R5-920, Biochemistry (medical), magnetic resonance spectroscopy, tissue frozen storage, 03 medical and health sciences, 0302 clinical medicine, human prostate, 030220 oncology & carcinogenesis, Molecular Medicine, High resolution magic angle spinning, lcsh:Medicine (General), metabolites, Original Research
Abstract

Accurate interpretation and correlation of tissue spectroscopy with pathological conditions requires disease-specific tissue metabolite databases; however, specimens for research are often kept in frozen storage for various lengths of time. Whether such frozen storage results in alterations to the measured metabolites is a critical but largely unknown issue. In this study, human prostate tissues from specimens that had been stored at –80 °C for 32 months were analyzed with high resolution magic angle spinning (HRMAS) magnetic resonance (MR) spectroscopy, and compared with the initial measurements of the adjacent specimens from the same cases when snap frozen in the operation room and kept frozen for less than 24 hours. Results of the current study indicate that that the storage-induced metabolite alterations are below the limits that tissue MR spectroscopy can discriminate. Furthermore, quantitative pathology evaluations suggest the observed alterations in metabolite profiles measured from the adjacent specimens of the same prostates may be accounted for by tissue pathological heterogeneities and are not a result of storage conditions. Hence, these results indicate that long-term frozen storage of prostate specimens can be quantitatively analyzed by HRMAS MR spectroscopy without concerns regarding significant metabolic degradation or alteration.

Published
2007

314. Genome-wide profiling of BK polyomavirus integration in bladder cancer of kidney transplant recipients reveals mechanisms of the integration at the nucleotide level

Author

Jin, Yu, Zhou, Yi, Deng, Wenfeng, Wang, Yuchen, Lee, Richard J., Liu, Yanna, Elias, Nahel, Hu, Yangcheng, Luo, Min-Hua, Liu, Rumin, Guan, Bowen, Geng, Jian, Xu, Jian, Ma, Junfeng, Zhou, Jiapeng, Liu, Na, Blute, Michael L., Colvin, Robert B., Wu, Chin-Lee, and Miao, Yun

Abstract

Chronic BK polyomavirus (BKPyV) infection is recognized as a potential oncogenic factor of urothelial carcinoma (UC) in renal transplant recipients. Recent studies have reported a positive correlation among BKPyV integration, persistent overexpression of viral large T antigen (TAg), and malignancy, yet little is known about the specific integration mechanisms and the impacts of viral integration. Here, we performed whole-genome sequencing (WGS) and viral capture-based sequencing on high-grade immunohistochemically TAg-positive UCs in two renal transplant recipients. A total of 181 integration sites, including the three found by WGS, were identified by viral capture-based sequencing, indicating its enhanced sensitivity and ability in identifying low-read integration sites in subpopulations of the tumor cells. The microhomologies between human and BKPyV genomes were significantly enriched in the flanking regions of 84.5% the integration sites, with a median length of 7?bp. Notably, 75 human genes formed fusion sequences due to viral insertional integration. Among them, the expression of 15 genes were statistically associated with UC based on GEO2R expression analysis. Our results indicated a multisite and multifragment linear integration pattern and a potential microhomology or nonhomologous end joining integration mechanism at the single-nucleotide level. We put forward a potential selection mechanism driven by immunity and centered on viral integration in the carcinogenesis of BKPyV.

Published
2021
Full Text
View/download PDF

315. Viral integration in BK polyomavirus-associated urothelial carcinoma in renal transplant recipients: multistage carcinogenesis revealed by next-generation virome capture sequencing

Author

Wang, Yuchen, Liu, Yanna, Deng, Wenfeng, Fu, Fangxiang, Yan, Susha, Yang, Hongwei, Liu, Rumin, Geng, Jian, Xu, Jian, Wu, Yihan, Ma, Junfeng, Zhou, Jiapeng, Liu, Na, Jin, Yu, Xia, Renfei, Elias, Nahel, Lee, Richard J., Feldman, Adam S., Blute, Michael L., Colvin, Robert B., Wu, Chin-Lee, and Miao, Yun

Abstract

BK polyomavirus (BKPyV)-associated cancer after transplantation has gained increasing attention. However, the role of BKPyV integration on oncogenesis is still unclear. In this study, next-generation virome capture sequencing of primary and metastatic tumors were performed in three patients with BKPyV-associated urothelial carcinoma after renal transplantation. As a result, a total of 332 viral integration sites were identified in the six tumors. Integration of BKPyV in both primary and metastatic tumors followed the mechanism of microhomology-mediated end joining mostly, since microhomologies between human and BKPyV genomes were significantly enriched in flanking regions of 84% of the integration sites. Viral DNA breakpoints were nonrandom and tended to assemble in large T gene, small T gene and viral protein 2 gene. There were three, one and one consensus integration sites between the primary and metastatic tumors, which affected LINC01924, eIF3c, and NEIL2genes in the three cases respectively. Thus, we concluded that integration of BKPyV was a continuous process occurring in both primary and metastatic tumors, generating heterogenous tumor cell populations. Through this ongoing process, certain cell populations might have gained growth advantage or metastatic potential, as a result of viral integration either affecting the cellular genes where the viral DNA integrated to or altering the expression or function of the viral genes.

Published
2020
Full Text
View/download PDF

316. The clinicopathological characteristics and prognostic value of squamous differentiation in patients with bladder urothelial carcinoma: a meta-analysis.

Author

Lin, Xueming, Deng, Tuo, Wu, Shulin, Lin, Sharron X., Wang, Dongwen, and Wu, Chin-Lee

Subjects
TRANSITIONAL cell carcinoma, BLADDER, TUMOR classification, PROGRESSION-free survival, BLADDER cancer
Abstract

Purpose: Urothelial carcinoma with squamous differentiation (UCSD) is the most common histologic variant in bladder cancer (BCa). Previously, some studies have linked the presence of UCSD with the risk of worse survival outcomes in BCa patients. However, such association is still controversial. In this study, we performed a meta-analysis to clarify the clinicopathological characteristics and to further investigate the prognostic value of UCSD in BCa. Methods: A systematic literature search was performed in electronic databases including PubMed, Embase, Chinese National Knowledge Infrastructure and Wanfang Data until October 2018. Subgroup analyses were performed according to different treatments and study outcomes. Results: Total of 13,284 patients were enrolled in 19 studies which were included in this meta-analysis. The percentage of female patients with UCSD was significantly higher than those with pure urothelial carcinoma. UCSD was correlated with tumor stage T3/T4, tumor grade 3, positive surgical margin, and lymph node involvement. Moreover, the recurrence rate was higher in patients with UCSD after surgery. UCSD was associated with poorer disease-free survival (DFS). No significant difference of cancer-specific survival (CSS) or overall survival (OS) was found on multivariable analysis between the two groups. Conclusions: Our study demonstrated that UCSD in BCa was associated not only with unfavorable clinicopathological features, but also with high risk of recurrence and poorer prognosis for DFS. However, UCSD is not independently significant for CSS and OS. Well-designed randomized study with larger sample size is warranted to verify the findings and to further explore the role of UCSD in BCa. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

317. Prognostic value of a gene signature in clear cell renal cell carcinoma.

Author

Chen, Liang, Luo, Yongwen, Wang, Gang, Qian, Kaiyu, Qian, Guofeng, Wu, Chin‐Lee, Dan, Han C., Wang, Xinghuan, and Xiao, Yu

Subjects
RENAL cell carcinoma, CANCER prognosis
Abstract

Renal cancer is a common urogenital system malignance. Novel biomarkers could provide more and more critical information on tumor features and patients' prognosis. Here, we performed an integrated analysis on the discovery set and established a three‐gene signature to predict the prognosis for clear cell renal cell carcinoma (ccRCC). By constructing a LASSO Cox regression model, a 3‐messenger RNA (3‐mRNA) signature was identified. Based on the 3‐mRNA signature, we divided patients into high‐ and low‐risk groups, and validated this by using three other data sets. In the discovery set, this signature could successfully distinguish between the high‐ and low‐risk patients (hazard ratio (HR), 2.152; 95% confidence interval (CI),1.509–3.069; p < 0.0001). Analysis of internal and two external validation sets yielded consistent results (internal: HR, 2.824; 95% CI, 1.601–4.98; p < 0.001; GSE29609: HR, 3.002; 95% CI, 1.113–8.094; p = 0.031; E‐MTAB‐3267: HR, 2.357; 95% CI, 1.243–4.468; p = 0.006). Time‐dependent receiver operating characteristic (ROC) analysis indicated that the area under the ROC curve at 5 years was 0.66 both in the discovery and internal validation set, while the two external validation sets also suggested good performance of the 3‐mRNA signature. Besides that, a nomogram was built and the calibration plots and decision curve analysis indicated the good performance and clinical utility of the nomogram. In conclusion, this 3‐mRNA classifier proved to be a useful tool for prognostic evaluation and could facilitate personalized management of ccRCC patients. The 3‐mRNA classifier proved be a useful tool for prognostic evaluation and could facilitate personalized management of ccRCC patients. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

318. Fifteen hub genes associated with progression and prognosis of clear cell renal cell carcinoma identified by coexpression analysis.

Author

Wang, Yejinpeng, Chen, Liang, Wang, Gang, Cheng, Songtao, Qian, Kaiyu, Liu, Xuefeng, Wu, Chin‐Lee, Xiao, Yu, and Wang, Xinghuan

Subjects
RENAL cell carcinoma
Abstract

Renal cell carcinoma (RCC) is the most common type of renal tumor, and the clear cell renal cell carcinoma (ccRCC) is the most frequent subtype. In this study, our aim is to identify potential biomarkers that could effectively predict the prognosis and progression of ccRCC. First, we used The Cancer Genome Atlas (TCGA) RNA‐sequencing (RNA‐seq) data of ccRCC to identify 2370 differentially expressed genes (DEGs). Second, the DEGs were used to construct a coexpression network by weighted gene coexpression network analysis (WGCNA). Moreover, we identified the yellow module, which was strongly related to the histologic grade and pathological stage of ccRCC. Then, the functional annotation of the yellow module and single‐samples gene‐set enrichment analysis of DEGs were performed and mainly enriched in cell cycle. Subsequently, 18 candidate hub genes were screened through WGCNA and protein–protein interaction (PPI) network analysis. After verification of TCGA's ccRCC data set, Gene Expression Omnibus (GEO) data set (GSE73731) and tissue validation, we finally identified 15 hub genes that can actually predict the progression of ccRCC. In addition, by using survival analysis, we found that patients of ccRCC with high expression of each hub gene were more likely to have poor prognosis than those with low expression. The receiver operating characteristic curve showed that each hub gene could effectively distinguish between localized and advanced ccRCC. In summary, our study indicates that 15 hub genes have great predictive value for the prognosis and progression of ccRCC, and may contribute to the exploration of the pathogenesis of ccRCC. We constructed a scale‐free weighted gene coexpression network analysis coexpression network, after a series of rigorous analysis and verification, we finally selected 15 hub genes, which are significantly related to the progress and prognosis of clear cell renal cell carcinoma (ccRCC), as well as could also significantly differentiate between localized and advanced ccRCC. Our study providing new research objects for studying the pathogenesis of ccRCC, they are also new potential therapeutic targets for ccRCC. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

319. Expression of PD‐L1 in tumor‐associated nerves correlates with reduced CD8+ tumor‐associated lymphocytes and poor prognosis in prostate cancer.

Author

Mo, Ru‐Jun, Han, Zhao‐Dong, Liang, Ying‐Ke, Ye, Jian‐Heng, Wu, Shu‐Lin, Lin, Sharron X., Zhang, Yan‐Qiong, Song, Sheng‐Da, Jiang, Fu‐Neng, Zhong, Wei‐De, and Wu, Chin‐Lee

Abstract

To investigate immune profile consisting of stromal PD‐L1 expression, inhibitory or non‐T‐cell inflamed tumor microenvironment that may predict response to anti‐PD‐L1/PD‐1 immunotherapy in prostate cancer, we validated the specificity of a PD‐L1 monoclonal antibody (E1L3N) and identified PD‐L1 specific expression in prostatic stromal nerve cells. PD‐L1 expression was analyzed in 73 primary prostate cancers and 7 castration‐resistant prostate cancers (CRPC) by immunohistochemistry (IHC) and resulting data from primary prostate cancers were correlated with tumor‐associated lymphocytes (TALs), clinicopathological characteristics and clinical outcome. PD‐L1 was expressed in the tumor cells in only one primary prostate cancer case and none of the CRPC. However, PD‐L1 was frequently observed in the nerve branches in the tumor‐associated stroma (69 of 73 cases, 94.5%), supported by colocalization with axonal marker PGP9.5. FoxP3‐, CD3‐ and CD8‐positive T lymphocytes were observed in 74.6% (47/63), 98.4% (62/63) and 100% (61/61) of the cases, respectively. The density of PD‐L1+ tumor‐associated nerves (TANs) was inversely correlated with that of CD8+ TALs. Higher density of PD‐L1+ TANs was significantly associated with biochemical recurrence (BCR) in Kaplan–Meier survival analysis (p = 0.016). In both univariate and multivariate Cox analysis, the density of PD‐L1+ TANs was independently prognostic of BCR. In conclusion, PD‐L1 expression is rare in prostate tumor cells but prevalent in TANs and negatively correlated with CD8+ TALs. Neuro‐immunological interaction may be a contribution to immune‐suppressive microenvironment. Combinatorial treatment regimen designs to neural PD‐L1 and TALs should be warranted in future clinical application of anti‐PD‐L1/PD‐1 immunotherapy in prostate cancer. What's new? Immunotherapies targeting programmed cell death protein 1 (PD‐1) and its ligand PD‐L1 display durable clinical benefit across various cancer types. However, an immunosuppressive tumor microenvironment has been suggested to underlie the resistance to anti‐PD‐L1/PD‐1 monotherapy in prostate cancer patients. This study investigates stromal PD‐L1 and its relationship with tumor‐associated lymphocytes (TALs) in prostate cancer. The findings indicate that PD‐L1 is expressed in tumor‐associated nerves (TANs) and that high density of PD‐L1+ TANs correlates with reduced CD8+ TALs and predicts poor prognosis of prostate cancer. Combinatorial treatment targeting neural PD‐L1 and TALs should be warranted in anti‐PD‐L1/PD‐1 immunotherapies for prostate cancer. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

320. Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development

Author

Broad Institute of MIT and Harvard, Oh, Coyin, Meyerson, Matthew L, Getz, Gad Asher, Boehm, Jesse S, Giannikou, Krinio, Malinowska, Izabela A., Pugh, Trevor J., Yan, Rachel, Tseng, Yuen-Yi, Kim, Jaegil, Tyburczy, Magdalena E., Chekaluk, Yvonne, Liu, Yang, Alesi, Nicola, Finlay, Geraldine A., Wu, Chin-Lee, Signoretti, Sabina, Henske, Elizabeth P., Kwiatkowski, David J., Broad Institute of MIT and Harvard, Oh, Coyin, Meyerson, Matthew L, Getz, Gad Asher, Boehm, Jesse S, Giannikou, Krinio, Malinowska, Izabela A., Pugh, Trevor J., Yan, Rachel, Tseng, Yuen-Yi, Kim, Jaegil, Tyburczy, Magdalena E., Chekaluk, Yvonne, Liu, Yang, Alesi, Nicola, Finlay, Geraldine A., Wu, Chin-Lee, Signoretti, Sabina, Henske, Elizabeth P., and Kwiatkowski, David J.

Abstract

Renal angiomyolipoma is a kidney tumor in the perivascular epithelioid (PEComa) family that is common in patients with Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM) but occurs rarely sporadically. Though histologically benign, renal angiomyolipoma can cause life-threatening hemorrhage and kidney failure. Both angiomyolipoma and LAM have mutations in TSC2 or TSC1. However, the frequency and contribution of other somatic events in tumor development is unknown. We performed whole exome sequencing in 32 resected tumor samples (n = 30 angiomyolipoma, n = 2 LAM) from 15 subjects, including three with TSC. Two germline and 22 somatic inactivating mutations in TSC2 were identified, and one germline TSC1 mutation. Twenty of 32 (62%) samples showed copy neutral LOH (CN-LOH) in TSC2 or TSC1 with at least 8 different LOH regions, and 30 of 32 (94%) had biallelic loss of either TSC2 or TSC1. Whole exome sequencing identified a median of 4 somatic non-synonymous coding region mutations (other than in TSC2/TSC1), a mutation rate lower than nearly all other cancer types. Three genes with mutations were known cancer associated genes (BAP1, ARHGAP35 and SPEN), but they were mutated in a single sample each, and were missense variants with uncertain functional effects. Analysis of sixteen angiomyolipomas from a TSC subject showed both second hit point mutations and CN-LOH in TSC2, many of which were distinct, indicating that they were of independent clonal origin. However, three tumors had two shared mutations in addition to private somatic mutations, suggesting a branching evolutionary pattern of tumor development following initiating loss of TSC2. Our results indicate that TSC2 and less commonly TSC1 alterations are the primary essential driver event in angiomyolipoma/LAM, whereas other somatic mutations are rare and likely do not contribute to tumor development.

Published
2017

321. Subtyping muscle-invasive bladder cancer to assess clinical response to trimodality therapy.

Author

Efstathiou, Jason A., primary, Gibb, Ewan, additional, Miyamoto, David Tomoaki, additional, Wu, Chin-Lee, additional, Drumm, Michael, additional, Lehrer, Jonathan, additional, Ashab, Hussam Al-Deen, additional, Erho, Nicholas, additional, du Plessis, Marguerite, additional, Ong, Kaye, additional, Bhat, Akshay, additional, Mouw, Kent William, additional, Davicioni, Elai, additional, and Shipley, William U., additional

Published
2017
Full Text
View/download PDF

322. Expression of β-globin by cancer cells promotes cell survival during blood-borne dissemination

Author

Zheng, Yu, primary, Miyamoto, David T., additional, Wittner, Ben S., additional, Sullivan, James P., additional, Aceto, Nicola, additional, Jordan, Nicole Vincent, additional, Yu, Min, additional, Karabacak, Nezihi Murat, additional, Comaills, Valentine, additional, Morris, Robert, additional, Desai, Rushil, additional, Desai, Niyati, additional, Emmons, Erin, additional, Milner, John D., additional, Lee, Richard J., additional, Wu, Chin-Lee, additional, Sequist, Lecia V., additional, Haas, Wilhelm, additional, Ting, David T., additional, Toner, Mehmet, additional, Ramaswamy, Sridhar, additional, Maheswaran, Shyamala, additional, and Haber, Daniel A., additional

Published
2017
Full Text
View/download PDF

323. CD13hi Neutrophil-like myeloid-derived suppressor cells exert immune suppression through Arginase 1 expression in pancreatic ductal adenocarcinoma

Author

Zhang, Jing, primary, Xu, Xiongfei, additional, Shi, Min, additional, Chen, Ying, additional, Yu, Danghui, additional, Zhao, Chenyan, additional, Gu, Yan, additional, Yang, Biao, additional, Guo, Shiwei, additional, Ding, Guiling, additional, Jin, Gang, additional, Wu, Chin-Lee, additional, and Zhu, Minghua, additional

Published
2017
Full Text
View/download PDF

324. Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer

Author

Saylor, Philip J., primary, Lee, Richard J., additional, Arora, Kshitij S., additional, Deshpande, Vikram, additional, Hu, Rong, additional, Olivier, Kara, additional, Meneely, Erika, additional, Rivera, Miguel N., additional, Ting, David T., additional, Wu, Chin-Lee, additional, and Miyamoto, David T., additional

Published
2017
Full Text
View/download PDF

326. Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development

Author

Giannikou, Krinio, primary, Malinowska, Izabela A., additional, Pugh, Trevor J., additional, Yan, Rachel, additional, Tseng, Yuen-Yi, additional, Oh, Coyin, additional, Kim, Jaegil, additional, Tyburczy, Magdalena E., additional, Chekaluk, Yvonne, additional, Liu, Yang, additional, Alesi, Nicola, additional, Finlay, Geraldine A., additional, Wu, Chin-Lee, additional, Signoretti, Sabina, additional, Meyerson, Matthew, additional, Getz, Gad, additional, Boehm, Jesse S., additional, Henske, Elizabeth P., additional, and Kwiatkowski, David J., additional

Published
2016
Full Text
View/download PDF

328. Abstract 2679: Induction of β-globin protects circulating tumor cells from oxidative stress during dissemination

Author

Zheng, Yu, primary, Miyamoto, David T., additional, Wittner, Ben S., additional, Sullivan, James P., additional, Aceto, Nicola, additional, Vincent Jordan, Nicole, additional, Yu, Min, additional, Karabacak, Nezihi Murat, additional, Comaills, Valentine, additional, Morris, Robert, additional, Desai, Rushil, additional, Desai, Niyati, additional, Emmons, Erin, additional, Lee, Richard J., additional, Wu, Chin-Lee, additional, Sequist, Lecia V., additional, Haas, Wilhelm, additional, Ting, David T., additional, Toner, Mehmet, additional, Ramaswamy, Sridhar, additional, Maheswaran, Shyamala, additional, and Haber, Daniel A., additional

Published
2016
Full Text
View/download PDF

330. Branched chain RNA in situ hybridization for androgen receptor splice variant AR-V7 as a prognostic biomarker for metastatic castration-sensitive prostate cancer.

Author

Lee, Richard J., primary, Saylor, Philip James, additional, Arora, Kshitij S., additional, Deshpande, Vikram, additional, Hu, Rong, additional, Olivier, Kara M., additional, Barrett, Erika D., additional, Rivera, Miguel N., additional, Ting, David Tsai, additional, Wu, Chin-Lee, additional, and Miyamoto, David Tomoaki, additional

Published
2016
Full Text
View/download PDF

333. MP49-17 CLINICAL OUTCOMES OF PATIENTS WITH HISTOLOGIC VARIANTS OF BLADDER CANCER TREATED WITH TRIMODAL BLADDER-SPARING THERAPY

Author

Krasnow, Ross, primary, Roberts, Hannah, additional, Drumm, Michael, additional, Niemierko, Andrzej, additional, Wu, Chin-Lee, additional, Feldman, Adam, additional, Wszolek, Matthew, additional, Lee, Richard, additional, Blute, Michael, additional, Zietman, Anthony, additional, Shipley, William, additional, and Efstathiou, Jason, additional

Published
2016
Full Text
View/download PDF

336. Cover Image.

Author

Giannikou, Krinio, Klonowska, Katarzyna, Tsuji, Junko, Wu, Shulin, Zhu, Zachary, Probst, Clemens K, Kao, Katrina Z, Wu, Chin‐Lee, Rodig, Scott, Marino‐Enriquez, Adrian, Zen, Yoh, Schaefer, Inga‐Marie, and Kwiatkowski, David J

Subjects
MACROPHAGES
Published
2023
Full Text
View/download PDF

337. Microphthalmia family of transcription factors associated renal cell carcinoma

Author

Xie, Ling, Zhang, Yifen, and Wu, Chin-Lee

Abstract

The microphthalmia (MiT) subfamily of transcription factors includes TFE3, TFEB, TFEC, and MITF. In the 2016 World Health Organization classification, MiT family translocation renal cell carcinoma (tRCC) including Xp11 tRCC and t(6;11) RCC, was newly defined as an RCC subtype. Xp11 and t(6;11) RCC are characterized by the rearrangement of the MiT transcription factors TFE3 and TFEB, respectively. Recent studies identified the fusion partner-dependent clinicopathological and immunohistochemical features in TFE3-rearranged RCC. Furthermore, RCC with TFEB amplification, Melanotic MiT family translocation neoplasms, was identified may as a unique subtype of MiT family associated renal neoplasms, along with MITF associated RCC. In this review, we will collect available literature of these newly-described RCCs, analyze their clinicopathological and immunohistochemical features, and summarize their molecular and genetic evidences. We expect this review would be beneficial for the understanding of these rare subtypes of RCCs, and eventually promote clinical management strategies.

Published
2024
Full Text
View/download PDF

339. Birt-Hogg-Dubé syndrome in an overall view: Focus on the clinicopathological prospects in renal tumors

Author

Wu, Jialong, Lu, Jian, Wu, Chin-Lee, and Lu, Min

Abstract

Birt-Hogg-Dubé syndrome (BHD) represents a rare autosomal dominant tumor predisposition syndrome characterized by skin lesions, lung cysts, and renal tumors. The predominant histological subtypes of BHD-related renal tumors include hybrid oncocytoma-chromophobe tumors, oncocytomas, and chromophobe renal cell carcinomas, all exhibiting eosinophilic/oncocytic features. Immunohistochemistry staining for KIT (CD117) and CK7 exhibits variability in these tumor types. Germline mutations in FLCN have been consistently identified. Generally, patients with BHD demonstrate a favorable prognosis with minimal metastatic potential. Nonetheless, the comprehensive elucidation of pathological characteristics of BHD remains incomplete, particularly in BHD-associated renal tumors that deviate from the previously identified subtypes, thereby complicating the differential diagnosis. In this review, we provide a comprehensive overview of BHD encompassing epidemiology, clinical manifestations, genetic and molecular pathogenesis, as well as clinical diagnostic modalities. Emphasis is placed on clinicopathological features, specifically focusing on BHD-associated renal tumors. Collectively, this review aims to present the latest insights into BHD which benefits in the early detection, therapeutic decision-making, and prognosis prediction in BHD cases, and deepen the understanding of sporadic renal tumors.

Published
2024
Full Text
View/download PDF

344. Abstract IA09: Single cell RNA-sequencing of circulating tumor cells

Author

Miyamoto, David T., primary, Zheng, Yu, additional, Wittner, Ben S., additional, Lee, Richard J., additional, Zhu, Huili, additional, Broderick, Katherine T., additional, Desai, Rushil, additional, Brannigan, Brian W., additional, Arora, Kshitij S., additional, Dahl, Douglas M., additional, Sequist, Lecia V., additional, Smith, Matthew R., additional, Kapur, Ravi, additional, Wu, Chin-Lee, additional, Shioda, Toshi, additional, Ramaswamy, Sridhar, additional, Ting, David T., additional, Toner, Mehmet, additional, Maheswaran, Shyamala, additional, and Haber, Daniel A., additional

Published
2016
Full Text
View/download PDF

346. Metformin represses cancer cells via alternate pathways in N-cadherin expressing vs. N-cadherin deficient cells.

Author

Ge, Rongbin, Wang, Zongwei, Wu, Shulin, Zhuo, Yangjia, Otsetov, Aleksandar G, Cai, Chao, Zhong, Weide, Wu, Chin-Lee, Olumi, Aria F, Ge, Rongbin, Wang, Zongwei, Wu, Shulin, Zhuo, Yangjia, Otsetov, Aleksandar G, Cai, Chao, Zhong, Weide, Wu, Chin-Lee, and Olumi, Aria F

Abstract

Metformin has emerged as a potential anticancer agent. Here, we demonstrate that metformin plays an anti-tumor role via repressing N-cadherin, independent of AMPK, in wild-type N-cadherin cancer cells. Ectopic-expression of N-cadherin develops metformin-resistant cancer cells, while suppression of N-cadherin sensitizes cancer to metformin. Manipulation of AMPK expression does not alter sensitivity of cancer to metformin. We show that NF-kappaB is a downstream molecule of N-cadherin and metformin regulates NF-kappaB signaling via suppressing N-cadherin. Moreover, we also suggest that TWIST1 is an upstream molecule of N-cadherin/NF-kappaB signaling and manipulation of TWIST1 expression changes the sensitivity of cancer cells to metformin. In contrast to the cells that express N-cadherin, in N-cadherin deficient cells, metformin plays an anti-tumor role via activation of AMPK. Ectopic expression of N-cadherin makes cancer more resistant to metformin. Therefore, we suggest that metformin's anti-cancer therapeutic effect is mediated through different molecular mechanism in wild-type vs. deficient N-cadherin cancer cells. At last, we selected 49 out of 984 patients' samples with prostatic cancer after radical prostatectomy (selection criteria: Gleason score ≥ 7 and all patients taking metformin) and showed levels of N-cadherin, p65 and AMPK could predict post-surgical recurrence in prostate cancer after treatment of metformin.

Published
2015
Full Text
View/download PDF

347. DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate.

Author

Ge, Rongbin, Wang, Zongwei, Bechis, Seth K, Otsetov, Alexander G, Hua, Shengyu, Wu, Shulin, Wu, Chin-Lee, Tabatabaei, Shahin, Olumi, Aria F, Ge, Rongbin, Wang, Zongwei, Bechis, Seth K, Otsetov, Alexander G, Hua, Shengyu, Wu, Shulin, Wu, Chin-Lee, Tabatabaei, Shahin, and Olumi, Aria F

Abstract

5-α Reductase type 2 (SRD5A2) is a critical enzyme for prostatic development and growth. Inhibition of SRD5A2 by finasteride is used commonly for the management of urinary obstruction caused by benign prostatic hyperplasia. Contrary to common belief, we have found that expression of SRD5A2 is variable and absent in one third of benign adult prostates. In human samples, absent SRD5A2 expression is associated with hypermethylation of the SRD5A2 promoter, and in vitro SRD5A2 promoter activity is suppressed by methylation. We show that methylation of SRD5A2 is regulated by DNA methyltransferase 1, and inflammatory mediators such as tumor necrosis factor α, NF-κB, and IL-6 regulate DNA methyltransferase 1 expression and thereby affect SRD5A2 promoter methylation and gene expression. Furthermore, we show that increasing age in mice and humans is associated with increased methylation of the SRD5A2 promoter and concomitantly decreased protein expression. Artificial induction of inflammation in prostate primary epithelial cells leads to hypermethylation of the SRD5A2 promoter and silencing of SRD5A2, whereas inhibition with tumor necrosis factor α inhibitor reactivates SRD5A2 expression. Therefore, expression of SRD5A2 is not static and ubiquitous in benign adult prostate tissues. Methylation and expression of SRD5A2 may be used as a gene signature to tailor therapies for more effective treatment of prostatic diseases.

Published
2015
Full Text
View/download PDF

348. Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2 : Implications for Personalized Therapy of Benign Prostatic Hyperplasia.

Author

Bechis, Seth K, Otsetov, Alexander G, Ge, Rongbin, Wang, Zongwei, Vangel, Mark G, Wu, Chin-Lee, Tabatabaei, Shahin, Olumi, Aria F, Bechis, Seth K, Otsetov, Alexander G, Ge, Rongbin, Wang, Zongwei, Vangel, Mark G, Wu, Chin-Lee, Tabatabaei, Shahin, and Olumi, Aria F

Abstract

PURPOSE: In men with symptomatic benign prostatic hyperplasia 5α-reductase inhibitors are a main modality of treatment. More than 30% of men do not respond to the therapeutic effects of 5α-reductase inhibitors. We have found that a third of adult prostate samples do not express 5α-reductase type 2 secondary to epigenetic modifications. We evaluated whether 5α-reductase type 2 expression in benign prostatic hyperplasia specimens from symptomatic men was linked to methylation of the 5α-reductase type 2 gene promoter. We also identified associations with age, obesity, cardiac risk factors and prostate specific antigen. MATERIALS AND METHODS: Prostate samples from men undergoing transurethral prostate resection were used. We determined 5α-reductase type 2 protein expression and gene promoter methylation status by common assays. Clinical variables included age, body mass index, hypertension, hyperlipidemia, diabetes, prostate specific antigen and prostate volume. Univariate and multivariate statistical analyses were performed followed by stepwise logistic regression modeling. RESULTS: Body mass index and age significantly correlated with methylation of the 5α-reductase type 2 gene promoter (p <0.05) whereas prostate volume, prostate specific antigen or benign prostatic hyperplasia medication did not correlate. Methylation highly correlated with 5α-reductase protein expression (p <0.0001). In a predictive model increasing age and body mass index significantly predicted methylation status and protein expression (p <0.01). CONCLUSIONS: Increasing age and body mass index correlate with increased 5α-reductase type 2 gene promoter methylation and decreased protein expression in men with symptomatic benign prostatic hyperplasia. These results highlight the interplay among age, obesity and gene regulation. Our findings suggest an individualized epigenetic signature for symptomatic benign prostatic hyperplasia, which may be important to choose appropriate personalized tr

Published
2015
Full Text
View/download PDF

349. miR-195 Inhibits Tumor Progression by Targeting RPS6KB1 in Human Prostate Cancer

Author

Cai, Chao, primary, Chen, Qing-Biao, additional, Han, Zhao-Dong, additional, Zhang, Yan-Qiong, additional, He, Hui-Chan, additional, Chen, Jia-Hong, additional, Chen, Yan-Ru, additional, Yang, Sheng-Bang, additional, Wu, Yong-Ding, additional, Zeng, Yan-Ru, additional, Qin, Guo-Qiang, additional, Liang, Yu-Xiang, additional, Dai, Qi-Shan, additional, Jiang, Fu-Neng, additional, Wu, Shu-lin, additional, Zeng, Guo-Hua, additional, Zhong, Wei-De, additional, and Wu, Chin-Lee, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results